Radiopharma developers Actithera and Nuclidium secured new venture capital rounds, underscoring investor interest in targeted radioligand therapies. Additional financing activities include private rounds for Varda and Renasant, as well as public offerings by Rhythm, Cogent, Soleno, and Milestone. These capital infusions reflect robust funding dynamics supporting next-generation radiopharmaceutical innovation.